Brief: Takeda Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of Tak-881 In Primary Immunodeficiency Disease (Pid)
04/05/2026 13:04
May 4 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T: TAKEDA ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 2/3 CLINICAL TRIAL OF TAK-881 IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) TAKEDA PHARMACEUTICAL CO LTD - TAK-881 SHOWS SAFETY, EFFICACY, AND TOLERABILITY COMPARABLE TO HYQVIA TAKEDA PHARMACEUTICAL CO LTD - TO SUBMIT TAK-881 FOR REGULATORY APPROVAL IN U.S., EU, JAPAN IN FY2026 Source text: ID:nBw5NXSr3a Further company coverage: 4502.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)